El hecho de que el corazón sea capaz de segregar hormonas, y que éstas se liberen en cantidades importantes ante determinadas situaciones cardiacas, ha abierto un horizonte lleno de esperanzas e incertidumbres.
Estas hormonas, denominadas péptidos natriuréticos, poseen propiedades diuréticas, natriuréticas y vasodilatadoras. Las utilizadas en clínica son el ANP, BNP y sus porciones terminales (NT-proANP y NT-proBNP).
Actualmente, la mayoría de estudios están realizados con el BNP, pero debido a su menor variabilidad y mayor vida media es esperable que en los próximos años se incrementen en gran medida el número de trabajos con NT-proBNP.
De cualquier forma, parece con suficiente evidencia en la actualidad que el nivel plasmático de estas hormonas será de gran ayuda en el diagnóstico, pronóstico, despistaje, control farmacológico y tratamiento de la insuficiencia cardiaca.
Palabras clave
Insuficiencia cardiaca
Péptidos natriuréticos
Este artículo solo puede leerse en
pdf
Bibliografía
[1.]
A.J. De Bold, H.B. Borenstein, A.T. Veress, H. Sonnenberg.
A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats.
Life Sci, (1981), 28 pp. 89-94
[2.]
A. Clerico, M. Emdin.
Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review.
Clinical Chemistry, (2004), 50 pp. 33-50
[3.]
N. Valli, A. Gobinet, L. Bordenave.
Review of 10 years of the clinical use of brain natriuretic peptide in cardiology.
J Lab Clin Med, (1999), 134 pp. 437-444
[5.]
C. Hall, L. Aaberge, O. Stokke.
In vitro stability of N-terminal proatrial natriuretic factor in unfrozen samples: an important prerequisite for its use as a biochemical parameter of atrial pressure in clinicl routine.
Circulation, (1995), 91 pp. 911-912
[6.]
N.C. Davidson, W.J. Coutie, A.D. Struthers.
N-terminal proatrial natriuretic petide and brain natriuretic peptide are stable for up to 6 hours in whole blood in vitro.
Circulation, (1995), 91 pp. 1276-1277
[7.]
T. Maack, M. Suzuki, F.A. Almeida, D. Nussenzveig, R.M. Scarborough, G.A. McEnroe, et al.
Physiological role of silent receptors of atrial natriuretic factor.
Science, (1987), 238 pp. 675-678
[8.]
G. McDovell, C. Patterson, S. Maguire, C. Shaw, D.P. Nicholls, C. Hall.
Variability of NT-proANP and C-ANP.
Eur J Clin Invest, (2002), 32 pp. 545-548
[9.]
H. Ruskoaho.
Cardiac hormones as diagnostic tools in heart failure.
Endocrine Rev, (2003), 24 pp. 341-356
[10.]
A. Clerico, M. Emdin.
Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review.
Clinical Chemistry, (2004), 50 pp. 33-50
[11.]
P.J. Hunt, T.G. Yandle, M.G. Nicholls, A.M. Richards, E.A. Espiner.
The amino-terminal portion of pro-brain natriuretic peptide (ProBNP) circulates in human plasma.
Biochem Biophys Res Commun, (1995), 214 pp. 1175-1183
[12.]
P.J. Hunt, A.M. Richards, M.G. NichoJls, T.G. Yandle, R.N. Doughty, E.A. Espiner.
Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-proBNP): a new marker of cardiac impairment.
Clin Endocrinol (Oxf), (1997), 47 pp. 287-296
[13.]
J. Mair, A. Hammerer-Lercher, B. Puschendorf.
The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure.
Clin Chem Lab Med, (2001), 39 pp. 571-588
[14.]
D.R. Murdoch, J. Byrne, R. Farmer, J.J. Morton.
Disparity between studies of the stability of BNP in blood: comparison of endogenous and exogenous peptide.
Heart, (1999), 81 pp. 212-213
[15.]
M. McNairy, N. Gardetto, P. Clopton, A. García, P. Krishnaswamy, R. Kazanegra, et al.
Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: implications for outpatient monitoring with B-type natriuretic peptide.
Am Heart J, (2002), 143 pp. 406-411
[16.]
B.M. Cheung, J.E. Dickerson, M.J. Ashby, M.J. Brown, J. Brown.
Effects of physiological increments in human alpha-atrial natriuretic peptide and human brain natriuretic peptide in normal male subjects.
Clin Sci (Lond), (1994), 86 pp. 723-730
[17.]
C.C. Lang, J.G. Motwani, W.J. Coutie, A.D. Struthers.
Clearance of brain natriuretic peptide in patients with chronic heart failure: indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor mechanism.
Clin Sci (Colch), (1992), 82 pp. 619-623
[18.]
Y. Ogawa, K. Nakao, M. Mukoyama, K. Hosoda, G. Shirakami, H. Arai, et al.
Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. The ventricle is a major site of synthesis and secretion of brain natriuretic peptide.
Circ Res, (1991), 69 pp. 491-500
[19.]
H. Yasue, M. Yoshimura, H. Sumida, K. Kikuta, K. Kugiyama, M. Jougasaki, et al.
Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure.
Circulation, (1994), 90 pp. 95-203
[20.]
P.R. Kalra, J.R. Clague, A.P. Bolger, S.D. Anker, P.A. Poole-Wilson, A.D. Struthers, et al.
Myocardial production of C-type natriuretic peptides in chronic heart failure.
Circulation, (2003), 107 pp. 571-573
[21.]
R.E. Lang, H. Thölken, D. Ganten, F.C. Luft, H. Ruskoaho, T. Unger.
Atrial natriuretic factor-a circulating hormone stimulated by volume loading.
Nature, (1985), 314 pp. 264-266
[22.]
H. Ruskoaho, H. Tholken, R. Lang.
Increase in atrial pressure releases atrial natriuretic peptide from isolated perfused rat hearts.
Pfluegers Arch, (1986), 407 pp. 170-174
[23.]
R.S. Vasan, E.J. Benjamin, M.G. Larson, E.P. Leip, T.J. Wang, P.W. Wilson, et al.
Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study.
JAMA, (2002), 288 pp. 1252-1259
[24.]
V. Franco, Y.F. Chen, S. Oparil, J.A. Feng, D. Wang, F. Hage, et al.
Atrial natriuretic peptide dose-dependently inhibits pressure overload-induced cardiac remodeling.
Hypertension, (2004), 44 pp. 746-750
[25.]
H. Yasue, K. Obata, K. Okumura, M. Kurose, H. Ogawa, K. Matsuyama, et al.
Increased secretion of atrial natriuretic polypeptide from the left ventricle in patients with dilated cardiomyopathy.
J Clin Invest, (1989), 83 pp. 46-54
[26.]
M. Mukoyama, K. Nakao, Y. Saito, Y. Ogawa, K. Hosoda, S. Suga, et al.
Increased human brain natriuretic peptide in congestive heart failure.
N Engl J Med, (1990), 323 pp. 757-758
[27.]
C.M. Wei, D.M. Heutlein, M.A. Perrela, A. Lerman, R.J. Rodeheffer, C.GA. McGregor, et al.
Natriuretic peptide system in human heart failure.
Circulation, (1993), 88 pp. 1004-1009
[28.]
K. Nakao, Y. Ogawa, S.I. Suga, H. Imura.
Molecular biology and biochemistry of the natriuretic peptide system.
J Hypertens, (1992), 10 pp. 907-912
[29.]
H. Ruskoaho.
Atrial natriuretic peptide: síntesis, release, and metabolism.
Pharmacol Rev, (1992), 44 pp. 479-602
[30.]
A.J. De Bold, B.G. Bruneau, M.L. Kuroski.
Mechanical and neuroendocrine regulation of the endocrine heart.
Cardiovas Res, (1996), 31 pp. 7-18
[31.]
S. Inoue, Y. Murakami, K. Sano, H. Katoh, T. Shimada.
Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation.
J Card Fail, (2000), 6 pp. 92-96
[32.]
P. Mäntymaa, O. Vuolteenaho, M. Marttila, H. Ruskoaho.
Atrial strech induces rapid increase in brain natriuretic peptide but not in atrial natriuretic peptide gene expresión in vitro.
Endocrinology, (1993), 133 pp. 1470-1473
[33.]
C.C. Lang, W.J. Coutie, T.K. Khong, A.M. Choy, A.D. Struthers.
Dietary sodium loading increases plasma brain natriuretic peptide levels in man.
J Hypertens, (1991), 9 pp. 779-782
[34.]
M.G. Buckley, N.D. Markandu, G.A. Sagnella, G.A. McGregor.
Brain and atrial natriuretic peptides: a dual peptide system of potential importance in sodium balance and blood pressure regulation in patients with essential hypertension.
J Hypertens, (1994), 12 pp. 809-813
[35.]
T. Ogawa, W. Linz, M. Stevenson, B.G. Bruneau, M.L. Kuroski, J.H. Chen, et al.
Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production.
Circulation, (1996), 93 pp. 2059-2067
[36.]
H. Tokola, N. Hautala, M. Marttila, J. Magga, S. Pikkarainen, R. Kerkela, et al.
Mechanical load-induced alterations in B-type natriuretic peptide gene expression.
Can J Physiol Pharmacol, (2001), 79 pp. 646-653
[37.]
M.A. Silver, A. Maisel, C.W. Yancy, P.A. McCullough, J.C. Burnett, G.S. Francis, et al.
BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases.
Heart Failure, (2004), 10 pp. 1-30
[38.]
A. Maisel, P. Krishnaswamy, R.M. Nowak, J. McCord, J.E. Hollander, P. Duc, et al.
Rapid measurement of B-type natriuretic peptide in the emergengy diagnosis of heart failure.
N Engl J Med, (2002), 347 pp. 161-167
[39.]
A. Maisel, J. Hollander, D. Guss, P. McCullough, R. Nowak, G. Green, et al.
Primary results of the rapid emergency department heart failure outpatients trial (REDHOT).
J Am Coll Cardiol, (2004), 44 pp. 1334-1336
[40.]
C. Mueller, A. Scholer, K. Laule-Kilian, B. Martina, C. Schindler, P. Buser, et al.
Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea.
N Engl J Med, (2004), 350 pp. 647-654
[41.]
D.L. Dries, D.V. Exner, M.J. Domanski, B. Greenberg, L.W. Stevenson.
The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction.
J Am Coll Cardiol, (2000), 35 pp. 681-689
[42.]
T. Akiba, K. Tachibana, K. Togaski, M. Hiroe, F. Marumo.
Plasma human brain natriuretic peptide in chronic renal failure.
Clin Nephrol, (1995), 44 pp. S61-S64
[43.]
National Kidney Foundation.
Clinical practice guidelins for chronic kidney disease: evaluation, classification and stratification.
Am J Kid Disease, (2002), 2 pp. S46-S75
[44.]
L.K. Morrison, A. Harrison, P. Krishnaswamy, R. Kazanegra, P. Clopton, A. Maisel.
Utility of a rapid B-natriuretic peptide (BNP) assay in differentiating HF from lung disease in patients presenting with dyspnea.
J Am Coll Cardiol, (2002), 39 pp. 202-209
[45.]
B. Berman, R. Spragg, A. Maisel.
B-type natriuretic peptide (BNP) levels in differentiating congestive heart failure from acute respiratory distress syndrome (ARDS).
Circulation, (2002), 106 pp. 191
[46.]
R. Sarzani, P. Dessi-Fulgheri, V.M. Paci, E. Espinosa, A. Rappelli.
Expresión of natriuretic peptide receptors un human adipose and other tisúes.
J Endocrinol Invest, (1996), 19 pp. 581-585
[47.]
C. Sengenes, M. Berlan, I. De Glisezinski, M. Lafontan, J. Galitzky.
Natriuretic peptides: a new lipolytic pathway in human adipocytes.
FASEB J, (2000), 14 pp. 1345-1351
[48.]
M.R. Mehra, P.A. Uber, M.H. Park, R.L. Scott, H.O. Ventura, B.C. Harris, et al.
Obesity and suppressed B-type natriuretic peptide levels in heart failure.
J Am Coll Cardiol, (2004), 43 pp. 1590-1595
[49.]
M. Rivera, R. Talens, A. Salvador, V. Bertomeu, V. Miró, F. García de Burgos, Grupo Disfunción VI Comunidad Valenciana, et al.
NT-proBNP e hipertensión. Su importancia en el diagnóstico de insuficiencia cardíaca.
Rev Esp Cardiol, (2004), 57 pp. 396-402
[50.]
M. Rivera, R. Talens, A. Salvador, V. Bertomeu, V. Miró, A. Jordán, Grupo de disfunción VI Comunidad Valenciana, et al.
Ventricular hypertrophy increases NT-proBNP in subjects with and without hypertension.
Int J Cardiol, (2004), 96 pp. 265-271
[51.]
J. Osca, A. Quesada, M.A. Arnau, A. Osa, I. Hervás, L. Almenar, et al.
Péptido cerebral natriurético. Valor diagnóstico en la insuficiencia cardiaca.
Rev Esp Cardiol, (2002), 55 pp. 7-15
[52.]
A.S. Maisel, J. McCord, R.M. Nowak, J.E. Hollander, A.H. Wu, P. Duc, et al.
Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction: results from the Breathing Not Properly (BNP) multinational study.
J Am Coll Cardiol, (2003), 41 pp. 2010-2017
[53.]
E. Lubien, A. DeMaria, P. Krishnaswamy, P. Clopton, J. Koon, R. Kazanegra, et al.
Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings.
Circulation, (2002), 105 pp. 595-601
[54.]
S. Kenchaiah, J.C. Evans, D. Levy, P.W. Wilson, E.J. Benjamin, M.G. Larson, et al.
Obesity and the risk of heart failure.
N Engl J Med, (2002), 347 pp. 358-359
[55.]
I.S. Anand, L.D. Fisher, Y.T. Chiang, R. Latini, S. Masson, A.P. Maggioni, et al.
Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).
Circulation, (2003), 107 pp. 1278-1283
[56.]
P. Bettencourt, S. Ferreira, A. Azevedo, A. Ferreira.
Preliminary data on the potential usefulness of B-type natriuretic peptide levels in predicting outcomes after hospital discharge in patients with heart failure.
Am J Med, (2002), 113 pp. 215-219
[57.]
R. Berger, M. Huelsman, K. Strecker, A. Bojic, P. Moser, B. Stanek, et al.
B-type natriuretic peptide predicts sudden death in patients with chronic heart failure.
Circulation, (2002), 105 pp. 2392-2397
[58.]
D.J. Bradley, E.A. Bradley, K.L. Baughman, R.D. Berger, H. Calkins, S.N. Goodman, et al.
Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trial.
JAMA, (2003), 289 pp. 730-740
[59.]
A.M. Sinha, K. Filzmaier, O.A. Breithardt, D. Kunz, J. Graf, K.U. Markus, et al.
Usefulnessof brain natriuretic release as a surrogate marker of the efficacy of long-term cardiac resynchronization theraphy in patients with heart failure.
Am J Cardiol, (2003), 91 pp. 755-758
[60.]
R.S. Vasan, E.J. Benjamin, M.G. Larson, E.P. Leip, T.J. Wang, P.W. Wilson, et al.
Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study.
JAMA, (2002), 288 pp. 1252-1259
[61.]
M.A. Silver, C. Pisano.
High incidence of elevated B-type natriuretic peptide levels and risk factors for heart failure in an unselected at-risk population (stage A): implications for heart failure screening programs.
Congest Heart Fail, (2003), 9 pp. 127-132
[62.]
M.R. Cowie, A.D. Struthers, D.A. Wood, A.J. Coats, S.G. Thompson, P.A. Poole-Wilson, et al.
Value of natriuretic peptides in assessment of patiens with possible new heart failure in primary care.
Lancet, (1997), 350 pp. 1349-1353
[63.]
M.I. Burgess, A. Bhattacharyya, S.G. Ray.
Echocardiography after cardiac transplantation.
J Am Soc Echocardiogr, (2002), 15 pp. 917-925
[64.]
M.R. Mehra, P.A. Uber, S. Potluri, H.O. Ventura, R.L. Scott, M.H. Park.
Usefulness of an elevated B-type natriuretic peptide to predict allograft failure, cardiac allograft vasculopathy, and survival after heart transplantation.
Am J Cardiol, (2004), 94 pp. 454-458
[65.]
M.A. Arnau, L. Almenar, I. Hervás, A. Osa, L. Martínez-Dolz, J. Rueda, et al.
Predictive value of brain natriuretic peptide in the diagnosis of heart transplant rejection.
J Heart Lung Transplant, (2004), 23 pp. 850-856
[66.]
R. Sodian, M. Loebe, C. Schmitt, E.V. Potapov, H. Siniawski, J. Muller, et al.
Decreased plasma concentrations of brain natriuretic pep-tide as a potential indicator of cardiac recovery in patients supported by mechanical circulatory assist systems.
J Am Coll Cardiol, (2001), 38 pp. 1942-1949
[67.]
A.M. Richards, R. Doughty, M.G. Nicholls, S. MacMahon, N. Sharpe, J. Murphy, et al.
Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.
J Am Coll Cardiol, (2001), 37 pp. 1781-1787
[68.]
R.W. Troughton, C.M. Frampton, T.G. Yandle, E.A. Espiner, M.G. Nicholls, A.M. Richards.
Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations.
Lancet, (2000), 355 pp. 1126-1130
[69.]
T.B. Horwich, J. Patel, W.R. MacLellan, G.C. Fonarow.
Cardiac troponina I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality in advanced heart failure.
Circulation, (2003), 108 pp. 833-838
[70.]
C.W. Yancy.
Treatment with B-type natriuretic peptide for chronic decompensated heart failure: insights learned from the follow-up serial infusion of nesiritide (FUSION) trial.
Heart Fail Rev, (2004), 9 pp. 209-216
[71.]
E.J. Topol.
Nesiritide: not verified.
N Engl J Med, (2005), 353 pp. 113-116
Copyright ©
2006. Sociedad Española de Cardiología